Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.

Seminars in cancer biology - 1 Oct 2020

Kobayashi Yoshie, Lim Seung-Oe, Yamaguchi Hirohito

Abstract excerpt

Immune checkpoint inhibitors (ICIs) are novel class of anti-cancer drugs that exhibit significant therapeutic effects even in patients with advanced-stage cancer. However, the efficacy of ICIs is limited due to resistance. Therefore, appropriate biomarkers to select patients who are likely to respond to these drugs as well as combination therapy to overcome the resistance are urgently necessary. Cancer is caused...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to B7-H1 Antigen
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immune Evasion

Share to Immunotherapy

Share to Neoplasms

Share to Signal Transduction

Source

Identifiers

PMID: 31874279
DOI: 10.1016/j.semcancer.2019.11.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.PMID 31874279Read ↗

The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy.Semantic proximity Read ↗

Genetic Dysregulation of Immunologic and Oncogenic Signaling Pathways Associated with Tumor-intrinsic Immune Resistance: A Molecular Basis for Combination Targeted Therapy-Immunotherapy for CancerSemantic proximity Read ↗

Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.Semantic proximity Read ↗

Mechanism of resistance to immune checkpoint inhibitorsSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.Semantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read ↗

The Resistance Mechanisms of Checkpoint Inhibitors in Solid TumorsSemantic proximity Read ↗

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitor for Lung AdenocarcinomaSemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.